Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk: A Pooled Analysis.


Journal

JAMA oncology
ISSN: 2374-2445
Titre abrégé: JAMA Oncol
Pays: United States
ID NLM: 101652861

Informations de publication

Date de publication:
01 02 2020
Historique:
pubmed: 28 10 2019
medline: 19 12 2020
entrez: 25 10 2019
Statut: ppublish

Résumé

Dietary fiber (the main source of prebiotics) and yogurt (a probiotic food) confer various health benefits via modulating the gut microbiota and metabolic pathways. However, their associations with lung cancer risk have not been well investigated. To evaluate the individual and joint associations of dietary fiber and yogurt consumption with lung cancer risk and to assess the potential effect modification of the associations by lifestyle and other dietary factors. This pooled analysis included 10 prospective cohorts involving 1 445 850 adults from studies that were conducted in the United States, Europe, and Asia. Data analyses were performed between November 2017 and February 2019. Using harmonized individual participant data, hazard ratios and 95% confidence intervals for lung cancer risk associated with dietary fiber and yogurt intakes were estimated for each cohort by Cox regression and pooled using random-effects meta-analysis. Participants who had a history of cancer at enrollment or developed any cancer, died, or were lost to follow-up within 2 years after enrollment were excluded. Dietary fiber intake and yogurt consumption measured by validated instruments. Incident lung cancer, subclassified by histologic type (eg, adenocarcinoma, squamous cell carcinoma, and small cell carcinoma). The analytic sample included 627 988 men, with a mean (SD) age of 57.9 (9.0) years, and 817 862 women, with a mean (SD) age of 54.8 (9.7) years. During a median follow-up of 8.6 years, 18 822 incident lung cancer cases were documented. Both fiber and yogurt intakes were inversely associated with lung cancer risk after adjustment for status and pack-years of smoking and other lung cancer risk factors: hazard ratio, 0.83 (95% CI, 0.76-0.91) for the highest vs lowest quintile of fiber intake; and hazard ratio, 0.81 (95% CI, 0.76-0.87) for high vs no yogurt consumption. The fiber or yogurt associations with lung cancer were significant in never smokers and were consistently observed across sex, race/ethnicity, and tumor histologic type. When considered jointly, high yogurt consumption with the highest quintile of fiber intake showed more than 30% reduced risk of lung cancer than nonyogurt consumption with the lowest quintile of fiber intake (hazard ratio, 0.67 [95% CI, 0.61-0.73] in total study populations; hazard ratio, 0.69 [95% CI, 0.54-0.89] in never smokers), suggesting potential synergism. Dietary fiber and yogurt consumption was associated with reduced risk of lung cancer after adjusting for known risk factors and among never smokers. Our findings suggest a potential protective role of prebiotics and probiotics against lung carcinogenesis.

Identifiants

pubmed: 31647500
pii: 2753175
doi: 10.1001/jamaoncol.2019.4107
pmc: PMC6813596
doi:

Substances chimiques

Dietary Fiber 0
Prebiotics 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e194107

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK056341
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA173640
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA182910
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Br J Nutr. 2007 May;97(5):993-1000
pubmed: 17381986
BMJ. 2011 Nov 10;343:d6617
pubmed: 22074852
Am J Respir Crit Care Med. 2004 Aug 1;170(3):279-87
pubmed: 15117740
Nat Rev Nephrol. 2016 Mar;12(3):169-81
pubmed: 26616538
Biomarkers. 2011 Sep;16(6):504-10
pubmed: 21812595
Am J Clin Nutr. 2013 Aug;98(2):594-619
pubmed: 23803885
Lancet. 2018 Nov 24;392(10161):2288-2297
pubmed: 30217460
Br J Pharmacol. 2016 Feb;173(4):635-48
pubmed: 26013585
Am J Epidemiol. 1985 Jul;122(1):51-65
pubmed: 4014201
Epidemiology. 2018 Mar;29(2):254-260
pubmed: 28901975
Am J Epidemiol. 2001 Dec 15;154(12):1089-99
pubmed: 11744511
Am J Epidemiol. 2004 Jan 1;159(1):83-93
pubmed: 14693663
Cell. 2016 Jun 2;165(6):1332-1345
pubmed: 27259147
Nature. 2016 Jul 06;535(7610):56-64
pubmed: 27383980
Am J Epidemiol. 2009 Jul 1;170(1):104-11
pubmed: 19451177
Int J Cancer. 2018 Nov 1;143(9):2168-2176
pubmed: 29752709
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Gastroenterology. 2013 Jul;145(1):113-120.e3
pubmed: 23567349
Am J Public Health. 2016 Sep;106(9):1567-72
pubmed: 27459459
Am J Epidemiol. 2010 Apr 1;171(7):776-84
pubmed: 20172921
Arch Intern Med. 2011 Jun 27;171(12):1061-8
pubmed: 21321288
Am J Epidemiol. 2008 Mar 1;167(5):570-8
pubmed: 18063592
Eur J Clin Nutr. 2004 Jan;58(1):17-23
pubmed: 14679362
Ann Med. 2015;47(6):430-40
pubmed: 26340330
Nat Med. 2014 Feb;20(2):159-66
pubmed: 24390308
Am J Epidemiol. 1992 Jul 15;136(2):192-200
pubmed: 1415141
Eur J Clin Nutr. 2000 Dec;54(12):900-17
pubmed: 11114689
Therap Adv Gastroenterol. 2013 Jan;6(1):39-51
pubmed: 23320049
Int J Cancer. 2011 Dec 1;129(11):2712-9
pubmed: 21607947
Public Health Nutr. 2008 Feb;11(2):183-95
pubmed: 17610761
Am J Epidemiol. 2006 Jun 1;163(11):1053-64
pubmed: 16624970
Stat Med. 2017 Feb 28;36(5):772-789
pubmed: 27910122
Int J Cancer. 2016 Jul 15;139(2):347-54
pubmed: 26954623
Int J Epidemiol. 1989 Dec;18(4):858-67
pubmed: 2621022
Ann Oncol. 2016 Jan;27(1):81-96
pubmed: 26371287
Stat Med. 2017 Feb 28;36(5):855-875
pubmed: 27747915
Am J Epidemiol. 1992 May 15;135(10):1114-26; discussion 1127-36
pubmed: 1632423
Eur J Immunol. 2018 Jan;48(1):39-49
pubmed: 28776643
Nat Rev Gastroenterol Hepatol. 2015 May;12(5):303-10
pubmed: 25824997
Eur J Clin Nutr. 1998 Oct;52(10):722-7
pubmed: 9805218
Am J Clin Nutr. 1997 Apr;65(4 Suppl):1220S-1228S; discussion 1229S-1231S
pubmed: 9094926
J Clin Oncol. 2017 Sep 10;35(26):3055-3064
pubmed: 28742456
Sci Rep. 2016 Feb 15;6:20624
pubmed: 26877260
Clin Nutr. 2017 Dec;36(6):1465-1472
pubmed: 27923508
Nutr Rev. 2009 Apr;67(4):188-205
pubmed: 19335713
J Assoc Off Anal Chem. 1985 Jul-Aug;68(4):677-9
pubmed: 2993226
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1060-1070
pubmed: 28264875
Eur J Epidemiol. 2013 Jun;28(6):503-11
pubmed: 23576215

Auteurs

Jae Jeong Yang (JJ)

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, Tennessee.

Danxia Yu (D)

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, Tennessee.

Yong-Bing Xiang (YB)

State Key Laboratory of Oncogene and Related Genes & Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

William Blot (W)

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

Emily White (E)

Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Kim Robien (K)

Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia.

Rashmi Sinha (R)

Division of Epidemiology & Genetics, National Cancer Institute, Bethesda, Maryland.

Yikyung Park (Y)

Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri.

Yumie Takata (Y)

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, Tennessee.
College of Public Health and Human Sciences, Oregon State University, Corvallis.

DeAnn Lazovich (D)

Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis.
Masonic Cancer Center, University of Minnesota, Minneapolis.

Yu-Tang Gao (YT)

State Key Laboratory of Oncogene and Related Genes & Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Xuehong Zhang (X)

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Qing Lan (Q)

Division of Epidemiology & Genetics, National Cancer Institute, Bethesda, Maryland.

Bas Bueno-de-Mesquita (B)

Department for Determinants of Chronic Diseases, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, the Netherlands.

Ingegerd Johansson (I)

Department of Odontology, Umeå University, Umeå, Sweden.

Rosario Tumino (R)

Cancer Registry and Histopathology Department, Civic-M.P. Arezzo Hospital, American Samoa, Ragusa, Italy.

Elio Riboli (E)

Faculty of Medicine, School of Public Health, Imperial College, London, United Kingdom.

Anne Tjønneland (A)

Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark.
Denmark Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

Guri Skeie (G)

Department of Community Medicine, UIT, The Arctic University of Norway, Tromsø, Norway.

J Ramón Quirós (JR)

Public Health Directorate, Asturias, Spain.

Mattias Johansson (M)

Genetic Epidemiology Group, International Agency for Research on Cancer, Lyons, France.

Stephanie A Smith-Warner (SA)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Wei Zheng (W)

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

Xiao-Ou Shu (XO)

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH